Settings and Study Design
This randomized controlled trial (RCT) was performed from June 2017 to October 2018 at the All India Institute of Medical Sciences (AIIMS), New Delhi, a tertiary care hospital in North India. The AIIMS ethics committee approved the study, and written informed consent was obtained from all participants. The study was done as per the ethics delineated in the Helsinki Declaration.
Patient Identification, Recruitment, Inclusion, and Exclusion Criteria
Individuals with T2DM, diagnosed at ≥ 30 years of age and willing to participate in the study as per protocol, were identified from the outpatient clinic of the Department of Endocrinology and Metabolism, AIIMS. Those with HbA1c 7.5–10% and on stable oral glucose-lowering agents for the last 3 months were eligible. Patients with stage 4 and 5 chronic kidney disease, chronic liver disease, cancer, terminal illness, severe non-proliferative diabetic retinopathy, proliferative diabetic retinopathy or macular edema, any cardiovascular event requiring hospitalization in the last 6 months or with active diabetic foot ulcer were excluded. In addition, patients on insulin or other parenteral diabetes therapies were excluded.
Procedure on Day of Testing and Measurements
Participants were advised to fast for at least 10 h for the first visit for the evaluation of the fasting plasma glucose, lipid profile, and HbA1c in the morning. Additional information such as the demographics and relevant medical and treatment history was collected. Weight, height, waist circumference, and blood pressure were recorded in fasting state using standard methods [11]. Serum total cholesterol, triglyceride, and high-density lipoprotein (HDL) cholesterol levels and glucose levels were measured directly using an automated biochemistry analyzer (Cobas Integra 400 plus; Roche Diagnostics, Mannheim, Germany). Low-density lipoprotein (LDL) cholesterol was calculated using the Friedewald equation, except in cases with serum triglyceride levels ≥ 400 mg/dl (4.5 mmol/l). Blood for HbA1c was measured by Toshiba G-8 (Tosoh Corp., Japan).
Intervention and Usual Care Details
Video-based lifestyle education program (VBLEP): The curriculum used in the D-CLIP diabetes prevention study was converted into a 12-week video-based reality television series [available as an app (free and commercial) from https://apps.apple.com/in/app/habits-diabetes-coach/id1016026169] [6, 9]. We further adapted and consolidated this content to create four sessions, delivered at weekly intervals, with permission from the developers of the reality television program (Janacare Solutions Private, Ltd, Bengaluru) (details provided in Table 1).
Table 1 Contents of the video-based lifestyle education program The participants in the usual care arm were prescribed dietary advice by a registered dietician and 30 min of walking at a speed of 5–6 km/h for at least 5 days a week.
We also evaluated yoga as an additional arm in this RCT to gain additional insights into this increasingly popular means of exercise in India. We used the same usual care group, against which each of the two lifestyle intervention arms was compared. This design benefited us as fewer participants (25% less) had to be recruited (using same usual group) with potential savings in cost and time. In this article we present and discuss the results of a video-based lifestyle education program compared with usual care.
Outcome Measures
The primary outcome measure was the difference in change in mean HbA1c between groups. Secondary outcome measurements were change in fasting plasma glucose (FPG), weight, body mass index (BMI), waist circumference, blood pressure, and lipid parameters.
Sample Size Calculation
With the following assumptions, mean HbA1c of 8.8, SD 0.6 [values from baseline parameters of individuals with HbA1c 7.5–10% enrolled at the Department of Endocrinology & Metabolism, AIIMS in the Delhi centre of INDEPENDENT (Integrating DEPrEssioN and Diabetes treatment) Study] [12], and a delta of 0.5 between the intervention and usual care arm, the estimated sample size was 36 in each arm. The assumed power and alpha were 90% and 2.5%, respectively. The alpha error adjusted for multiple testing as the study intended to compare two different lifestyle intervention programs vs. usual care (see details at trial registration site CTRI registration no.: CTRI/2017/05/008564).
Randomization, Allocation Concealment, and Blinding
Patients were randomized in a 1:1 ratio using block randomization with varying block size by computer-generated random numbers. Allocation concealment was done by using sequentially numbered opaque sealed envelopes. Since the intervention was apparent, the trial was open-labeled and non-blinded. However, end point outcome assessment was done by a person who was not aware of the patient group to remove bias.
Statistical Analysis
Stata 12.0 (College Station, TX, USA) was used for statistical analysis. Pearson chi-square test was used to compare qualitative baseline variables among the groups. Quantitative baseline variables were compared using student’s t-test or wilcoxan rank sum test (as appropriate). Intention-to-treat and per protocol analysis was done for primary outcome. The difference in change in secondary outcomes in the two groups was assessed by per protocol analysis. The effect of VBLEP on primary and secondary outcomes compared with the usual care group was analyzed using linear regression analysis. The adjustment for the baseline serum triglyceride level was done in adjusted analysis as it was different at baseline between the two arms. The predictors associated with favorable outcome (difference in HbA1c ≥ 0.5% from baseline) were determined using logistic regression analysis, and the results are expressed as odds ratio (95% CI). The results are reported as the difference in changes between the two groups (95% CI). Data are presented as number (%), mean ± SD, or median (q25–q75) as appropriate. p < 0.025 was considered statistically significant.